200
Participants
Start Date
January 14, 2025
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
I-124 evuzamitide
I-124 evuzamitide, single dose imaging agent, administered intravenously.
RECRUITING
Columbia University, New York
NOT_YET_RECRUITING
University of Pittsburgh Medical Center, Pittsburgh
RECRUITING
Cone Health, Greensboro
RECRUITING
Duke University, Durham
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Cleveland Clinic, Weston
RECRUITING
Cleveland Clinic, Cleveland
NOT_YET_RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Northwestern University, Chicago
RECRUITING
Cook County Health, Chicago
RECRUITING
Washington University of St. Louis, St Louis
RECRUITING
St. Lukes (CVIT) Saint Luke's Health System, Kansas City
NOT_YET_RECRUITING
Houston Methodist, Houston
NOT_YET_RECRUITING
Mayo Clinic, Scottsdale
NOT_YET_RECRUITING
City of Hope - Duarte, Duarte
NOT_YET_RECRUITING
University of California, San Francisco
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Yale Cardiovascular Medicine, New Haven
RECRUITING
Brigham and Women's Hospital, Boston
NOT_YET_RECRUITING
Rutgers, New Brunswick
Collaborators (1)
Attralus, Inc.
INDUSTRY
Sharmila Dorbala
OTHER